Clinical and Biochemical Effects of Verapamil Administration to Schizophrenic Patients

David Pickar, Owen M. Wolkowitz, Allen R. Doran, Rodrigo Labarca, Alec Roy, Alan Breier, Prem K. Narang

Research output: Contribution to journalArticle

56 Citations (Scopus)

Abstract

We administered verapamil hydrochloride, a calcium channel antagonist, to seven chronically ill schizophrenic patients for five weeks under double-blind, placebo-controlled conditions. No therapeutic effect was noted. Worsening in hostile and uncooperative behaviors and a syndrome of heightened emotional tone was observed during verapamil treatment and during the postverapamil placebo period. Verapamil produced significant increases in cerebrospinal fluid (CSF) and plasma levels of homovanillic acid and in plasma levels of prolactin, as well as significant decreases in plasma levels of 3-methoxy-4-hydroxyphenethyleneglycol. Verapamil and its active metabolite, norverapamil, were partitioned into CSF with CSF/plasma ratios of 0.06 and 0.04, respectively. The lack of therapeutic effects of verapamil in schizophrenic patients differs from earlier reports of its usefulness in treating manic patients. The biochemical and clinical data from our study suggest the possibility that verapamil exerts behaviorally relevant central nervous system activity in schizophrenic patients.

Original languageEnglish (US)
Pages (from-to)113-118
Number of pages6
JournalArchives of General Psychiatry
Volume44
Issue number2
DOIs
StatePublished - 1987
Externally publishedYes

Fingerprint

Verapamil
Cerebrospinal Fluid
Therapeutic Uses
Placebos
Homovanillic Acid
Calcium Channel Blockers
Prolactin
Plasma
Chronic Disease
Central Nervous System
Placebo
Therapeutics

ASJC Scopus subject areas

  • Arts and Humanities (miscellaneous)
  • Psychiatry and Mental health

Cite this

Clinical and Biochemical Effects of Verapamil Administration to Schizophrenic Patients. / Pickar, David; Wolkowitz, Owen M.; Doran, Allen R.; Labarca, Rodrigo; Roy, Alec; Breier, Alan; Narang, Prem K.

In: Archives of General Psychiatry, Vol. 44, No. 2, 1987, p. 113-118.

Research output: Contribution to journalArticle

Pickar, David ; Wolkowitz, Owen M. ; Doran, Allen R. ; Labarca, Rodrigo ; Roy, Alec ; Breier, Alan ; Narang, Prem K. / Clinical and Biochemical Effects of Verapamil Administration to Schizophrenic Patients. In: Archives of General Psychiatry. 1987 ; Vol. 44, No. 2. pp. 113-118.
@article{327cfd498c724b70882ea588d63ac96c,
title = "Clinical and Biochemical Effects of Verapamil Administration to Schizophrenic Patients",
abstract = "We administered verapamil hydrochloride, a calcium channel antagonist, to seven chronically ill schizophrenic patients for five weeks under double-blind, placebo-controlled conditions. No therapeutic effect was noted. Worsening in hostile and uncooperative behaviors and a syndrome of heightened emotional tone was observed during verapamil treatment and during the postverapamil placebo period. Verapamil produced significant increases in cerebrospinal fluid (CSF) and plasma levels of homovanillic acid and in plasma levels of prolactin, as well as significant decreases in plasma levels of 3-methoxy-4-hydroxyphenethyleneglycol. Verapamil and its active metabolite, norverapamil, were partitioned into CSF with CSF/plasma ratios of 0.06 and 0.04, respectively. The lack of therapeutic effects of verapamil in schizophrenic patients differs from earlier reports of its usefulness in treating manic patients. The biochemical and clinical data from our study suggest the possibility that verapamil exerts behaviorally relevant central nervous system activity in schizophrenic patients.",
author = "David Pickar and Wolkowitz, {Owen M.} and Doran, {Allen R.} and Rodrigo Labarca and Alec Roy and Alan Breier and Narang, {Prem K.}",
year = "1987",
doi = "10.1001/archpsyc.1987.01800140015002",
language = "English (US)",
volume = "44",
pages = "113--118",
journal = "JAMA Psychiatry",
issn = "2168-622X",
publisher = "American Medical Association",
number = "2",

}

TY - JOUR

T1 - Clinical and Biochemical Effects of Verapamil Administration to Schizophrenic Patients

AU - Pickar, David

AU - Wolkowitz, Owen M.

AU - Doran, Allen R.

AU - Labarca, Rodrigo

AU - Roy, Alec

AU - Breier, Alan

AU - Narang, Prem K.

PY - 1987

Y1 - 1987

N2 - We administered verapamil hydrochloride, a calcium channel antagonist, to seven chronically ill schizophrenic patients for five weeks under double-blind, placebo-controlled conditions. No therapeutic effect was noted. Worsening in hostile and uncooperative behaviors and a syndrome of heightened emotional tone was observed during verapamil treatment and during the postverapamil placebo period. Verapamil produced significant increases in cerebrospinal fluid (CSF) and plasma levels of homovanillic acid and in plasma levels of prolactin, as well as significant decreases in plasma levels of 3-methoxy-4-hydroxyphenethyleneglycol. Verapamil and its active metabolite, norverapamil, were partitioned into CSF with CSF/plasma ratios of 0.06 and 0.04, respectively. The lack of therapeutic effects of verapamil in schizophrenic patients differs from earlier reports of its usefulness in treating manic patients. The biochemical and clinical data from our study suggest the possibility that verapamil exerts behaviorally relevant central nervous system activity in schizophrenic patients.

AB - We administered verapamil hydrochloride, a calcium channel antagonist, to seven chronically ill schizophrenic patients for five weeks under double-blind, placebo-controlled conditions. No therapeutic effect was noted. Worsening in hostile and uncooperative behaviors and a syndrome of heightened emotional tone was observed during verapamil treatment and during the postverapamil placebo period. Verapamil produced significant increases in cerebrospinal fluid (CSF) and plasma levels of homovanillic acid and in plasma levels of prolactin, as well as significant decreases in plasma levels of 3-methoxy-4-hydroxyphenethyleneglycol. Verapamil and its active metabolite, norverapamil, were partitioned into CSF with CSF/plasma ratios of 0.06 and 0.04, respectively. The lack of therapeutic effects of verapamil in schizophrenic patients differs from earlier reports of its usefulness in treating manic patients. The biochemical and clinical data from our study suggest the possibility that verapamil exerts behaviorally relevant central nervous system activity in schizophrenic patients.

UR - http://www.scopus.com/inward/record.url?scp=0023153488&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023153488&partnerID=8YFLogxK

U2 - 10.1001/archpsyc.1987.01800140015002

DO - 10.1001/archpsyc.1987.01800140015002

M3 - Article

VL - 44

SP - 113

EP - 118

JO - JAMA Psychiatry

JF - JAMA Psychiatry

SN - 2168-622X

IS - 2

ER -